The EuroPain Consortium met at the Barcelona Science Park
The partners of the EuroPain Consortium met at the Barcelona Science Park (PCB) on the 26th and 27th of October to kick off their project "Understanding pain and improving its treatment", the aim of which is to foster the development of new analgesics to improve the treatment of patients with chronic pain and increase the knowledge on the mechanisms involved in its onset. This is a 5-year long initiative with an overall allocated budget in excess of 15 milions Euros.
EuroPain is composed of the Catalan SME, Neuroscience Technologies, based at the Barcelona Science Park and dedicated to biomedical research in the field of neuropathic pain; three large European pain consortia: the London Pain Consortium (LPC), the German Neuropathic PainResearch Network (DFNS) iand the Danish Pain Research Center (DPRC), ; and nine large pharmaceutical comapnies members of the European Federation of Pharmaceuticl Industries and Associations (EFPIA): Astra Zeneca, Boehringer Ingelheim, Pfizer, Eli Lilly, GlaxoSmithKline, Wyeth, Esteve, UCB and Sanofi Aventis.
The mission of the EuroPain consortium is to create an international team of leading researchers and clinicians, from both academica and industry, to undertake multidisciplinary translational research which will increase the understanding of chronic pain mechanisms, facilitate the development of novel analgesics, and improve the treatment of chronic pain patients.
“Understanding pain and improving its treatment” aims to undertake six programms interlinked in the field of experimental research, underpinned and coordinated by a training and bioinformatics facility. Two of these research programmes will study pain in preclinical models; three will explore human pain mechanisms, and a sixth programme will integrate the data obtained via a common data warehouse.
This EuroPain project won the 1st Grant Call “Topic 9: Pain Research”, organised by the Innovative Drugs Initiative (IMI). IMI is an alliance between the European pharmaceutical industry (represented by the EFPIA) and the European Comission, duly constituted in December 2007 with the aim of fostering research and the development of new novel drugs in the EU at a lower cost. The initiative, equally financedby the European Comission -via the 7th Framework Programme- and the EFPA, has a total budget of 2,000 million Euros covering up to 2012, which will serve to fund research projects aimed at developing innovative new drugs.